← All countries · Western Pacific
80.5%
MCV1
2003 · Administrative (country-reported)
84.7%
DTP3
2003 · Administrative (country-reported)
85.6%
HepB3
2003 · Administrative (country-reported)
10
Measles cases
2025 reported
7
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99.4%2025 · Administrative (country-reported) | 99.4% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 87.8%2003 · Administrative (country-reported) | 87.8% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 84.7%2003 · Administrative (country-reported) | 84.7% | D · poor | |
| IPV1First dose of inactivated polio vaccine | —% · Administrative (country-reported) | — | too few points | D · poor |
| IPV completeInactivated polio vaccine, complete primary series | —% · Administrative (country-reported) | — | too few points | D · poor |
| MCV1First dose of measles-containing vaccine | 80.5%2003 · Administrative (country-reported) | 80.5% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 96.1%2025 · Administrative (country-reported) | 96.1% | D · poor | |
| RCV1First dose of rubella-containing vaccine | —% · Administrative (country-reported) | — | too few points | D · poor |
| HepB3Third dose of hepatitis B vaccine | 85.6%2003 · Administrative (country-reported) | 85.6% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 99.5%2025 · Administrative (country-reported) | 99.5% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 102025 | 1.4per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | A · strong | |
| Mumps all countries · vaccine evidence | 382025 | 5.1per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 72025 | 0.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02020 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | A · strong | |
| Invasive meningococcal disease all countries · vaccine evidence | 112025 | 1.5per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 102025 | 1.4per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (38 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | M18 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Travellers to endemic areas of hepatitis A. Men who have sex with men | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Travellers | Travellers to endemic areas of hepatitis A. Men who have sex with men | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y16 | Catch-up children | School Immunisation Teams provide Hepatitis B Vaccine mop-up to Primary 6 students who have not received 3 doses of Hepatitis B Vaccine on schedule. Adult Hepatitis B vaccine would be provided for school children who are aged 16 and above (mostly studying at special schools). |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y16 | General/routine | School Immunisation Teams provide Hepatitis B Vaccine mop-up to Primary 6 students who have not received 3 doses of Hepatitis B Vaccine on schedule. Adult Hepatitis B vaccine would be provided for school children who are aged 16 and above (mostly studying at special schools). |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Health care workers, people living with HIV, methadone clinic attendees, indicated patients in Social Hygiene Clinics and clients of Elderly Health Service, Women Health Service and Families Clinics who are family members/ sexual partners of people with known HBV infection | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10 | HPV for females only | female only |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | Y11 | HPV for females only | female only |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y50 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y17 | General/routine | Aged 6 months to 17 years (including children aged 18 years or above but still studying at secondary school) |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M18-Y6 | General/routine | Children born on or after 1 Jul 2018 receive MMRV vaccine at 18 months old, and children born between 1 Jan 2013 and 30 Jun 2018 receive MMRV vaccine in Primary 1 |
| MPOXMpox (monkeypox) vaccine | 1 | Health workers | Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong | |
| MPOXMpox (monkeypox) vaccine | 1 | Risk group(s) | Individuals with high risk sexual practices, e.g. men who have sex with men (MSM), having multiple sexual partners, sex workers, history of sexually transmitted infection within the past 12 months; Healthcare workers responsible for caring of patients with confirmed Mpox; Laboratory personnel working with zoonotic pox viruses; and Animal care personnel with high risk of exposure in case of Mpox occurrence in animals in Hong Kong | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | >=Y65 | Risk group(s) | Individuals with high risk conditions who have received 23vPPV or who have not received any pneumococcal vaccines before. It is used to replace PCV13 for use in the Government pneumococcal vaccination programme since 5 August 2024. |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M4 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >=Y65 | Risk group(s) | Individuals with high risk conditions who have received PCV13/PCV15 or who have not received any pneumococcal vaccines before / Individuals without high risk conditions who have not received any pneumococcal vaccines before |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 1 | Pregnant women | Pregnant women | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 6 | Y11 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.